Key result
Gene therapy approaches, including gene replacement, exon skipping, and RNA interference, are emerging as promising etiological treatments for primary cardiomyopathies and are entering clinical practice.
Gene therapy for cardiomyopathies is rapidly advancing from preclinical models to late-stage clinical trials, particularly for Duchenne muscular dystrophy-associated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Gene therapies for cardiomyopathies remain experimental; leaves open their clinical role pending definitive trial data.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Лавров et al. (2023) conducted a review in Non-ischemic (primary) cardiomyopathies. Gene therapy (genome editing, RNA interference, antisense oligonucleotides, AAV vectors) was evaluated. Gene therapy approaches, including gene replacement, exon skipping, and RNA interference, are emerging as promising etiological treatments for primary cardiomyopathies and are entering clinical practice.
Synapse has enriched 10 related papers. Consider them for comparative context: